Big hopes for schizophrenia treatment rely on a deep pipeline of new approaches

Innovation in schizophrenia has been slow, and patients are often left with few options — but pharmas contribute to a robust lineup of candidates that could improve care.

By Kelly Bilodeau • March 6, 2024

HIV isn’t ‘solved,’ but a doctor who treated some of the first patients hopes to finally deliver a cure

From San Francisco in the 80s to a gene therapy prospect, Dr. Marcus Conant looks back on his long fight against the virus — and if the industry is close to ending the epidemic.

By Michael Gibney • March 5, 2024

Explore the Trendline➔

Artificial intelligence & machine learning

After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

By PharmaVoice staff

After ‘tragic’ bacterial outbreak, lawmakers press FDA to step up foreign inspections

Impatience to fix long-held challenges to overseas drug facility inspections is growing on Capitol Hill.

By Amy Baxter • March 1, 2024

A pandemic-era staffing crunch in clinical trials is easing, but trouble spots remain

How research companies can shift strategies to attract and retain the staff that keeps trials humming along. 

By Kelly Bilodeau • Feb. 28, 2024

Can a top scientist and Moderna co-founder change the CRO game?

From his advisory board role at Lindus Health, Robert Langer is aiming to overcome challenges in the CRO market.

By Michael Gibney • Feb. 28, 2024

Behind a big-name rare disease biotech, an exec draws from personal experience

The personal impact of rare disease has shaped Gianluca Pirozzi, a senior vice president at AstraZeneca’s Alexion, as a parent and drug developer.

By Alexandra Pecci • Feb. 27, 2024

How a 15-year-old Genzyme drug shortage became a legal smorgasbord of pharma’s thorniest issues

Rare disease treatments, drug shortages, a market monopoly and march-in rights all play a role in the story of newly revived litigation against Sanofi’s Genzyme.

By Alexandra Pecci • Feb. 26, 2024

AbbVie CEO Richard Gonzalez leaves a divisive Humira legacy and lasting impact on pharma

Leading AbbVie to become one of the most successful pharmas in the world, Gonzalez also rubbed some critics the wrong way.

By Michael Gibney • Feb. 22, 2024

4 biotechs to watch in 2024

A splashy IPO, first-in-class treatments and upcoming approval dates are a few reasons we’ve got our eyes on these biotechs this year.

By Alexandra Pecci • Feb. 21, 2024

Biden or Trump: How deeply will 2024’s election outcome impact pharma?

The election is still months away, but campaign promises are solidifying, and signal the benefits and drawbacks of each candidate for pharma.

By Michael Gibney • Feb. 20, 2024

Kite’s next-gen CAR-T aims include quicker production and more disease targets

While buzz builds around “off the shelf” CAR-T cell therapies, Kite is staying competitive with a shorter manufacturing turnaround and a focus on broadening applications.

By Kelly Bilodeau • Feb. 20, 2024

Value and potential of IoT and AI for chronic diseases treatment

A significant growth is predicted for both AI and IoT in healthcare. By 2030, the AI market is expected to reach $187.95 billion USD, while the IoT market is projected to climb even higher to $312.7 billion USD.

By Olena Domanska, Data Science Engineering Manager at Avenga • Feb. 20, 2024

‘Hey, AI: Is Zoloft effective for me?’ Tech’s foray into predictive prescribing

Researchers are unleashing the powers of AI for precision medicine, drug development and more.

By Alexandra Pecci • Feb. 15, 2024

The roadblocks faced by Biogen are many, but execs point to an R&D-focused turnaround

A disappointing few years for Biogen have led leadership to use new drug launches as fuel for an about-face.

By Michael Gibney • Feb. 15, 2024

‘I wish I could see the end of the day’ — a Pfizer exec on the fight for health equity

The pharma giant’s leader of a collective devoted to health equity discusses how companies can put their money where their mouth is to reach communities in need.

By Michael Gibney • Feb. 14, 2024

These 4 drugs had tons of promise — and they flopped. What happened?

No amount of excitement can prevent failures stemming from safety, efficacy, cost and other speed bumps along the way.

By Alexandra Pecci • Feb. 13, 2024

3 questions hanging over the Novo-Catalent deal

As backlash builds for the recently announced matchup, critical questions remain over its impact.

By Kelly Bilodeau • Feb. 13, 2024

A new (old) mind-opening tool in the fight against Alzheimer’s disease

A new use for an existing ultrasound technology is seeing early success in getting medications past the blood-brain barrier.

By Kelly Bilodeau • Feb. 12, 2024

Astellas’ science chief on the leap into new technologies

After a big 2023, Yoshi Shitaka said the company is banking on gene therapies, KRAS degraders and more to keep the momentum.

By Meagan Parrish • Feb. 9, 2024

Big Pharma players Amgen, Roche and Pfizer seek to follow in Novo and Lilly’s weight loss footsteps

While Novo Nordisk and Eli Lilly have a sizable lead in the quickly expanding GLP-1 market, Big Pharma peers are looking for a way in.

By Michael Gibney • Feb. 8, 2024

Pharma has a misinformation problem — and execs could be on the hook

Investment heavyweights BlackRock and Glass Lewis want compensation clawbacks on execs who don’t protect a company’s reputation. 

By Kelly Bilodeau • Feb. 7, 2024

‘Beginning of the end’ for small molecules? VCs brace for Medicare investment gap

The "small molecule penalty" becomes even riskier for investors as the IRA negotiates prices, and VCs and lawmakers are looking to get a jump on those headwinds.

By Michael Gibney • Feb. 6, 2024

Government hits patent thickets on multiple fronts

Patent thickets are the latest target in lawmakers' bid to lower drug prices.

By Alexandra Pecci • Feb. 5, 2024

Could Novo, Lilly become first trillion-dollar healthcare companies?

Explosive demand for weight loss drugs has propelled both companies to new heights. Here’s a look at the staggering growth, by the numbers.

By Meagan Parrish • Feb. 2, 2024

Merck keeps deal focus with Keytruda patent cliff on horizon

The company is open to deals the size of its prior Acceleron and Prometheus buyouts. “We continue to believe we need more,” CEO Rob Davis said.

By Ned Pagliarulo • Feb. 1, 2024